Event: Innovation in Antiretrovirals to Meet Developing Country Needs

Medicines Patent Pool, UNITAID, WHO and Chatham House

10 St James’s Square, London 10-11 July 2011

On 10-11 July 2011, the Medicines Patent Pool, UNITAID, WHO and the Chatham House brought together invited experts and representatives working on the treatment of HIV to identify challenges and opportunities for innovation in antiretroviral treatment specifically aimed at the needs of developing countries.

The meeting’s agenda is available here [pdf]. Biographies of the speakers and respondents are available here [pdf]. The Medicines Patent Pool, UNITAID, and the World Health Organization HIV/AIDS Department’s joint submission to the WHO Expert Committee on Essential Medicines, detailing missing drug formulations needed for HIV treatment, is a useful background document and is available here [pdf].

The presentations from the event are linked below in PDF format, where available. A report on the meeting’s outcomes is available here [pdf].


Welcome and Meeting Objectives:

  • Dr David Heymann, Head and Senior Fellow, Centre on Global Health Security, Chatham House

The Medicines Patent Pool’s Role in HIV Treatment Innovation for Resource-Limited Settings:

  • Ms Ellen ‘t Hoen, Executive Director, Medicines Patent Pool presentation

SESSION 1: Implementing a Short-­term Innovation Agenda

Presentations and general discussion chaired by Dr Mariangela Simao, Chief, Prevention, Vulnerability and Rights Division, UNAIDS


  • Prof. Francois Venter, Associate Professor in the Department of Medicine, University of Witwatersrand, South Africa presentation
  • Mr Craig McClure, Senior Adviser on Treatment 2.0 and Care Programme, WHO presentation


  • Dr Paul Stoffels, Company Group Chairman, Global Research & Development, Pharmaceuticals, Johnson & Johnson
  • Dr Yusuf K. Hamied, Managing Director, Cipla
  • Mrs Achara Eksaengsri, Director of Research and Development Institute, The Government Pharmaceutical Organization, Thailand
  • Dr Zengani Chirwa, ART Technical Advisor, Ministry of Health, Malawi
  • Dr David Ripin, Scientific Director, Drug Access Program, CHAI

SESSION 2: Responding to Specific Needs of Paediatric HIV Treatment

Presentations and general discussion chaired by Ms. Polly Clayden, Co-­Director, HIV i-­Base, London


  • Dr Ashraf Coovadia, Head of Empilweni Services and Research Unit, Department of Paediatrics, University of the Witwatersrand, South Africa presentation
  • Dr Shing Chang, R&D Director, Drugs for Neglected Diseases Initiative (DNDi) presentation


  • Ms Hanne Bak Pedersen, Deputy Director, Programme, UNICEF Supply Division
  • Dr Lillian Lou, Medical Director, International Access Operations, Gilead Sciences
  • Dr Tendani Gaolathe, Chairperson of the national Clinical management committee of HIV and AIDS, Botswana
  • Mr Anirudh Deshpande, Sr. Vice President. Matrix Laboratories Limited

SESSION 3: Funding and Novel Incentives to Promote Innovation in HIV

Panel discussion and Presentations chaired by Mr Andrew Jack, the Financial Times

Keynote speaker:

  • Hon Stephen O’Brien MP, Parliamentary Under-­‐Secretary of State for International Development of the UK


  • Prof. Rifat Atun, Director Strategy, Performance & Evaluation Cluster, Global Fund to Fight AIDS, Tuberculosis and Malaria presentation
  • Dr Philippe Duneton, Deputy Executive Secretary, UNITAID
  • Prof. Charles Mgone, Executive Director, European & Developing Countries Clinical Trials Partnership presentation
  • Ms Pontso Maruping, executive responsible, Technology Innovation Agency (TIA), South Africa presentation
  • Dr Mohga Kamal-­‐Yanni, Senior Health Officer, OXFAM
  • Mr James Love, Director, Knowledge Ecology International presentation
  • Mr Shailesh Pednekar, General Manager, ARV Business and Global Therapy Management, Ranbaxy

SESSION 4: Exploring Medium-­ and Long‐Term Opportunities for Innovation in ART

Panel discussion and Presentations chaired by Dr Pedro Cahn, Director, Fundación Huesped, former President of the International AIDS Society


  • Dr Emily Erbelding, Deputy Director, NIH/NIAID Division of Acquired Immunodeficiency Syndrome (DAIDS) presentation
  • Prof. Beatriz Grinsztejn, Head of the STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz presentation


  • Dr John Pottage, Chief Medical & Science Officer, ViiV Healthcare
  • Dr John Erickson, CEO, Sequoia Pharmaceuticals
  • Dr Nathan Ford, Medical Coordinator, MSF Access Campaign

Comments are closed.